Landscapes / Companies
Nanjing Leads Biolabs Co.,Ltd not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials · 8 in all
Trials
13 active
20 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 24 Dec 2026Phase 2 trial completes | |||
| Next date | 24 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumour, Advanced Solid Tumor and 6 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 20 Sep 2029Phase 1/2 trial completes | |||
| Next date | 20 Sep 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory Multiple Myeloma | ||||
| Open drug page | |||||
— |
Phase 1 | 16 Dec 2027Phase 1 trial completes | |||
| Next date | 16 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
About
- No active trial
- Alcestobart, LBL-003, LBL-015, LBL-019, LBL-033
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021